Prof Adam Waldman
MRC Institute of Genetics & Molecular Medicine CANCER RESEARCH UK Imaging
The overall theme of my research is development and validation of quantitative and molecular imaging biomarkers which reflect key features of genetics and metabolism in human glioma, for clinical stratification, therapeutic planning and drug development:
Experimental phase MRI and PET imaging studies of intermediary metabolism, validated against tissue metabolic markers from defined tumour regions; for more reliable tumour characterisation, and identification of potential therapeutic targets.
Translational multi-centre platform studies of early therapeutic response in GBM using quantitative diffusion imaging for improved endpoints in clinical trials and clinical decision-making.
Quantitative MRI for treatment stratification and planning in adult supratentorial low grade glioma.
Development of PET-MRI methodology and co-analysis for improved glioma characterization.
Integration of quantitative MRI and PET into surgical neuro-navigation systems, for improved targeting for biopsy and surgical resection.
Biomarkers in Adult Glioma
EVEN MORE SEMINARS
Mani Naghibi St. Mark's Hospital
Using nutrition therapies to positively effect cancer treatment outcomes
Imran Liaquat MBChB BSc MedSci MRCS FRCS MEd NHS Lothian, Scotland
Optimising Surgical Resection in Low Grade Glioma Patients
Gareth Thomas BDS, MScD, PhD, FDSRCS, FRCPath University Hospital Southampton NHS Foundation Trust.
Targeted therapies: aiming at the tumour micro-environment
Dr Ioanna Nixon Beatson West of Scotland Cancer center, NHS Greater Glasgow and Clyde
When the oncologist meets the patient: value of compassion. How well are we doing?
Chris Curtis The Swallows Head & Neck Cancer Charity
A patient’s journey ‘Cancer to the palace in 6yrs’